Whittemore-Peterson Invites Patients to Participate in Neuro-Immune Database & Be Considered for Emerging Clinical Trials

WPI Offers Link to Online Questionnaire

Source: Whittemore-Peterson Institute announcement received via Co-Cure Listserv, Nov 16, 2009

Research Studies and Clinical Trials

New treatment strategies for immune modulation and antiviral strategies have been successfully developed for chronic inflammatory disease over the last decade. Each of these drugs has had to undergo extensive investigation before obtaining approval for general use.

A critical need is sub grouping the spectrum of neuro-immune disease in order to stratify patients according to the appropriate therapy. The current translational and clinical research studies at WPI have clinical trials as endpoints.

While WPI currently has no open clinical trials, when trials are initiated they will offer patients the opportunity to participate in clinical trials that are designed to test the effectiveness of new forms of therapy. Clinical trials are voluntary, and our team will only involve patients who are entirely comfortable with the process.

Another critical need is a comprehensive database of patients with information on your diagnosis, conditions, family health and similar items.

You can help by completing the research questionnaire and including your information for our researchers to study.

All clinical trials conducted here at WPI are approved and closely monitored by the University of Nevada’s Institutional Review Board (IRB). No WPI staff have any financial interests or holdings in the various pharmaceutical companies who produce drugs used to treat chronic diseases.

If you would like to be considered for participation in current or upcoming clinical trials, and include your information in our research database, please complete this research questionnaire.


For more information, please contact:
Research Program Coordinator
Whittemore Peterson Institute
6600 N. Wingfield Parkway
Sparks, NV 89436

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)

Leave a Reply